- Home
- JLL vs GMAB Comparison
JLL vs GMAB Comparison
Compare JLL & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JLL
- GMAB
- Stock Information
- Founded
- JLL 1997
- GMAB 1999
- Country
- JLL United States
- GMAB Denmark
- Employees
- JLL N/A
- GMAB N/A
- Industry
- JLL Real Estate
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- JLL Finance
- GMAB Health Care
- Exchange
- JLL Nasdaq
- GMAB Nasdaq
- Market Cap
- JLL 12.8B
- GMAB 13.9B
- IPO Year
- JLL 1997
- GMAB N/A
- Fundamental
- Price
- JLL $275.50
- GMAB $21.42
- Analyst Decision
- JLL Buy
- GMAB Buy
- Analyst Count
- JLL 8
- GMAB 7
- Target Price
- JLL $312.43
- GMAB $37.80
- AVG Volume (30 Days)
- JLL 379.1K
- GMAB 968.5K
- Earning Date
- JLL 08-06-2025
- GMAB 08-11-2025
- Dividend Yield
- JLL N/A
- GMAB N/A
- EPS Growth
- JLL 47.74
- GMAB 276.80
- EPS
- JLL 11.64
- GMAB 18.36
- Revenue
- JLL $24,676,200,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- JLL $12.53
- GMAB $21.64
- Revenue Next Year
- JLL $8.13
- GMAB $15.57
- P/E Ratio
- JLL $23.46
- GMAB $1.17
- Revenue Growth
- JLL 13.47
- GMAB 25.43
- 52 Week Low
- JLL $194.36
- GMAB $17.24
- 52 Week High
- JLL $288.50
- GMAB $27.94
- Technical
- Relative Strength Index (RSI)
- JLL 66.19
- GMAB 46.21
- Support Level
- JLL $262.33
- GMAB $21.26
- Resistance Level
- JLL $282.63
- GMAB $22.27
- Average True Range (ATR)
- JLL 6.69
- GMAB 0.34
- MACD
- JLL 0.60
- GMAB -0.11
- Stochastic Oscillator
- JLL 77.07
- GMAB 11.50
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.